Prothena (PRTA)
(Delayed Data from NSDQ)
$20.56 USD
0.00 (0.00%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $20.67 +0.11 (0.54%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 181 - 200 ( 329 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
PRX002 Safety and Biomarker Data Support Ph 2 Start this Quarter, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Assuming Coverage, FY16 Results, Expecting Continued Progress in All Fronts in 2017, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Phase I/II Data Presented at ASH Consistent with Full NEOD001 Data; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
ASH 2016: Additional Abstracts and Sessions of Interest
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
PRX002 with Higher CSF Levels Than Expected - Phase II up Next; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H